Blueprint Medicines
BPMC
$107.19
Share price
0.18%
Change (1 day)
106.61%
Change (1 year)
Categories
Revenue for Blueprint Medicines (BPMC)
Revenue in 2023 (TTM): $0.24 B
According to Blueprint Medicines
's latest financial reports the company's current revenue (TTM
) is $0.24 B.
In 2022 the company made a revenue of $0.20 B an increase over the years 2021 revenue that were of $0.18 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Blueprint Medicines from 2015 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $0.24 B | 22.22% |
| 2022 | $0.20 B | 13.3% |
| 2021 | $0.18 B | -77.31% |
| 2020 | $0.79 B | 1093.37% |
| 2019 | $66.51 M | 49.39% |
| 2018 | $44.52 M | 107.79% |
| 2017 | $21.42 M | -22.85% |
| 2016 | $27.77 M | 143.61% |
| 2015 | $11.4 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pacific Biosciences
PACB | $0.20 B | -19.59% | 🇺🇸 USA |
 OPKO Health
OPK | $0.86 B | 246.26% | 🇺🇸 USA |
 Acceleron Pharma XLRN | $0.11 B | -54.78% | 🇺🇸 USA |
 Isoray
ISR | $8.96 M | -96.40% | 🇺🇸 USA |